– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases – – Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions – Sept. 09, 2025 -- Tourmaline Bio, Inc. (“Tourmaline”) (NAS

- Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to provide update at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET - Sept. 09, 2025 -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it has entered into a definitive agreement to sell its EluPro™ an

Dura Medical, together with pending acquisitions of Neurospa TMS and Cohen & Associates, to provide contiguous coverage at more than 8 locations along Florida’s West Coast, with planned coverage throughout the Florida Peninsula Dura delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to Veterans and civilian patients Stephen Durand, CRNA, a US Army Veteran and founder of Dura will serve as

Sept. 05, 2025 -- OrthoPediatrics Corp. (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics announced today a new distribution partnership with MY01, an innovative medical technology company focused on transforming the diagnosis of limb perfusion injuries. This collaboration will expand access to MY01’s Continuous Perfusion Sensing Technology™ (CPST™) Platform for children and adolescents, a population at great risk for acute compartment syndrome. Acut

Sept. 04, 2025 -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, announced today that it has awarded a new $1.0 million grant to Axovia Therapeutics to support the clinical development of AXV-101, an investigational gene therapy aimed at combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1). This is the organization’s third major grant in support of the program, bringing it

Sept. 04, 2025 -- Science 37, the leader in expanding patient access to clinical trials, and Catalent®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by providing reli

- Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - - Revised guidance of pro forma 2025 combined revenues, now estimated to be in the range of $325 to $350 million - - Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million -

Sept. 02, 2025 -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026. "T

Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting Sept. 02, 2025 -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today a

August 28, 2025 ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics. Collaboration with Roche Diagnostics is first major commercial step to significantly advance adoption of ProNephro AKI across US hospital institutions. August 28 – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), today announced ProNephro AKI (NGAL), the Company’s test for acute kidney injury, is now commercially avai